← All Dexcom INC filings

Dexcom INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
DXCM
Dexcom INC
DEF: DexCom Sets May 27th Annual Meeting, Reports Strong 2025 Growth
DexCom, Inc. announced its 2026 Annual Meeting of Stockholders, highlighting robust 2025 financial and operational achievements, including significant revenue and income growth, new product launches, and expanded customer access.
NASDAQ
DXCM
Dexcom INC
DEFA14A: DexCom Director Karen Dahut Resigns Ahead of 2025 Annual Meeting
DexCom announces the resignation of director Karen Dahut, effective May 8, 2025, just before the company's annual shareholder meeting.
NASDAQ
DXCM
Dexcom INC
DEFA14A: DexCom, Inc. Files Definitive Proxy Statement
DexCom, Inc. has filed a definitive proxy statement with the SEC.
NASDAQ
DXCM
Dexcom INC
DEF: DexCom Seeks Stockholder Approval for Amended Equity Incentive and Employee Stock Purchase Plans
DexCom is asking stockholders to approve amendments to its equity incentive and employee stock purchase plans to extend their terms and increase the number of shares available for issuance.
NASDAQ
DXCM
Dexcom INC
DEF 14A: DexCom, Inc. Announces Details for 2024 Annual Stockholders Meeting, Highlights 2023 Financial Performance
DexCom, Inc.'s proxy statement details the agenda for the 2024 annual stockholders meeting and reviews the company's strong 2023 financial results, including a 24% increase in revenue.